U.S. Markets open in 4 hrs

BMS/ Celgene Deal Could Spark M/A Activity

HENDERSON, NV / ACCESSWIRE / January 8, 2019 / Bristol-Myers Squibb announced a deal Thursday, buying Celgene Corp. for $74 billion. Investors in other growing cancer treatment companies should pay attention, as CELG investors received 1 share of BMS as well as $50 cash for every share of CELG they own.

One intriguing company that could draw investment interest from blue-chip companies like BMS, Delcath Systems, Inc. (DCTH), has an impressive liver cancer treatment in late-stage development, is already in clinical trials, increased their revenue this past year, and just signed a licensing deal with a projected value of up to $45 million. The stock is still a relative unknown, so start your research on DCTH today.

Today we are highlighting: Delcath Systems, Inc. (DCTH), Celgene Corporation (CELG), Bristol-Myers Squibb Company (BMY), Cronos Group, Inc. (CRON), and Viking Therapeutics, Inc. (VKTX).

An interventional oncology company focused on treating liver cancers with some serious upside potential, Delcath Systems, Inc. (DCTH) (Market Cap: $3.054M, Share Price: $0.31) ended 2018 with significant news. The company made major news when it announced a new licensing agreement for CHEMOSAT® commercialization in Europe with medac Gesellschaft für klinische Spezialpräparate mbH (medac). The agreement has a projected value of up to $45 million over the first seven-year term and includes an optional five-year extension. medac is a privately held, multi-national pharmaceutical company based in Hamburg area, Germany. Founded in 1970, medac specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases. The company has offices globally, worldwide partner agreements in over 90 countries, and approximately 1,200 employees.

The medac licensing agreement comes in addition to an announcement about the independent Data Safety Monitoring Board (DSMB) of the Registration trial for Patients with Hepatic Dominant Ocular Melanoma (The FOCUS Trial) completed another pre-specified review (the fourth) of safety data for treated patients in the trial. This review was conducted on data collected from both the prior randomized protocol and the amended single-arm protocol for the FOCUS Trial. The DSMB again recommended continuation of the study without modification.

Also in 2018, Delcath amended their Phase 3 clinical trial, raised $7 million via a rights offering, increased revenue 20% Y/Y, and had data published in European Radiology among several other milestones.

With news like this DCTH could attract investor interest in the coming sessions.

____

Bristol-Myers Squib said Celgene Corporation (CELG)'s (Market Cap: $61.285B, Share Price: $87.52) investors would receive one Bristol-Myers share and $50 in cash for each Celgene holding, as well as a special rights issue that will pay off if the merged group meets certain business targets. The deal values the cancer drug specialist at $74 billion.

____

Bristol-Myers Squibb Company (BMY) (Market Cap: $79.027B, Share Price: $48.41) made major waves on Wall Street Thursday with the buyout of Celgene.

____

Another biotech receiving major investment dollars, Cronos Group, Inc. (CRON) (Market Cap: $2.179B, Share Price: $12.40), has received over $14 billion from Altria for a 45% stake in the company.

____

Another liver cancer play like DCTH, Viking Therapeutics, Inc. (VKTX) (Market Cap: $613.841M, Share Price: $8.59) a clinical-stage biopharma company focused on the development of novel therapies for metabolic and endocrine disorders announced the presentation of results from the company's 12-week Phase 2 study of VK2809, its novel liver-selective thyroid receptor beta agonist, in patients with non-alcoholic fatty liver disease (NAFLD) and elevated low-density lipoprotein cholesterol (LDL-C).

Legal Disclaimer:

This article was written by Regal Consulting, LLC (“Regal Consulting”). Regal Consulting has agreed to a twelve-month term consulting agreement with DCTH dated 8/31/18. The agreement calls for $40,000 in cash, and 15,000 restricted 144 shares of DCTH per month. Issuer agreed to increase monthly cash payment in September to $120,000. All payments were made directly by Delcath Systems, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspecultors.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. DCTH was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.

http://www.regalconsultingllc.com/full legal disclaimer/

Microspeculators.com Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators

Contact Person: Media Manager

Email: info@microcapspeculators.com

Phone: 1-702-720-6310

Country: United States

Website: http://microcapspeculators.com/

SOURCE: ACR Communications LLC